These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 17353924

  • 1. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L, Brandes AA.
    Br J Cancer; 2007 Apr 10; 96(7):1047-51. PubMed ID: 17353924
    [Abstract] [Full Text] [Related]

  • 2. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
    Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C.
    Int J Radiat Oncol Biol Phys; 2008 Mar 15; 70(4):993-1001. PubMed ID: 17967517
    [Abstract] [Full Text] [Related]

  • 3. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M.
    J Clin Oncol; 2004 Dec 01; 22(23):4779-86. PubMed ID: 15570079
    [Abstract] [Full Text] [Related]

  • 4. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
    Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M, Gruppo Italiano Cooperativo di Neuro-Oncologia.
    J Clin Oncol; 2004 May 01; 22(9):1598-604. PubMed ID: 15117981
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
    Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, Chaigneau L, Carrasco AT, Viens P.
    Gynecol Oncol; 2008 Jan 01; 108(1):42-6. PubMed ID: 17980406
    [Abstract] [Full Text] [Related]

  • 6. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, Morikawa A, Atagi S, Kawahara M.
    Clin Lung Cancer; 2011 Nov 01; 12(6):387-92. PubMed ID: 21729650
    [Abstract] [Full Text] [Related]

  • 7. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 8. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.
    Lung Cancer; 2006 Jan 15; 51(1):89-96. PubMed ID: 16290256
    [Abstract] [Full Text] [Related]

  • 9. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J.
    Clin Cancer Res; 2013 Feb 15; 19(4):900-8. PubMed ID: 23363814
    [Abstract] [Full Text] [Related]

  • 10. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
    Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH.
    Lung Cancer; 2006 Apr 15; 52(1):93-7. PubMed ID: 16488055
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of gefitinib in recurrent glioblastoma.
    Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS.
    J Clin Oncol; 2004 Jan 01; 22(1):133-42. PubMed ID: 14638850
    [Abstract] [Full Text] [Related]

  • 12. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R, Nobile M, Rudà R, Borgognone M, Costanza A, Laguzzi E, Mutani R.
    Cancer; 2004 Feb 15; 100(4):807-13. PubMed ID: 14770438
    [Abstract] [Full Text] [Related]

  • 13. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
    Yung WK, Kyritsis AP, Gleason MJ, Levin VA.
    Clin Cancer Res; 1996 Dec 15; 2(12):1931-5. PubMed ID: 9816151
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
    Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK.
    Clin Cancer Res; 2005 Aug 01; 11(15):5539-48. PubMed ID: 16061871
    [Abstract] [Full Text] [Related]

  • 15. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL, Cancer and Leukemia Group B (CALGB 30101).
    Clin Cancer Res; 2005 Mar 15; 11(6):2300-4. PubMed ID: 15788680
    [Abstract] [Full Text] [Related]

  • 16. Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
    Schwer AL, Kavanagh BD, McCammon R, Gaspar LE, Kleinschmidt-De Masters BK, Stuhr K, Chen C.
    Int J Radiat Oncol Biol Phys; 2009 Apr 01; 73(5):1352-7. PubMed ID: 19013723
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
    Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S.
    J Clin Oncol; 2012 Apr 20; 30(12):1358-63. PubMed ID: 22393086
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE.
    Clin Cancer Res; 2005 Dec 01; 11(23):8418-24. PubMed ID: 16322304
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE.
    J Clin Oncol; 2003 May 15; 21(10):1980-7. PubMed ID: 12743152
    [Abstract] [Full Text] [Related]

  • 20. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS.
    Lung Cancer; 2011 Jan 15; 71(1):65-9. PubMed ID: 20430469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.